(Q50588175)

16 March 2018

title

Ribavirin and immune thrombocytopenic purpura. (English)

1 reference

16 March 2018

1 reference

1 reference

A Jaccard

1

1 reference

16 March 2018

V Loustaud

2

1 reference

16 March 2018

P Turlure

3

1 reference

16 March 2018

S Rogez

4

1 reference

16 March 2018

D Bordessoule

5

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 May 1998

1 reference

16 March 2018

published in

The Lancet

1 reference

16 March 2018

volume

351

1 reference

16 March 2018

issue

9116

1 reference

16 March 2018

page(s)

1660-1661

1 reference

16 March 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2977719-9

7 January 2021

Hepatitis C virus infection and autoimmune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2977719-9

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2977719-9

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2977719-9

7 January 2021

Ribavirin therapy for cryoglobulinemia and thrombocytopenia associated with hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2977719-9

7 January 2021

10.1016/S0140-6736(05)77719-9

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

9620744

1 reference

16 March 2018